The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Certification reinforces energy efficiency, sustainability goals, and green manufacturing across SMT’s Surat and Hyderabad facilities
Patalganga plant received zero observation from USFDA earlier
The association is intended to strengthen healthcare delivery standards, particularly in Oncology services, and enhance patient care outcomes
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The agreement could rise to $900 million if key commercial milestones are met
The Danish biotech company confirmed the global study will begin in the second half of 2026
Subscribe To Our Newsletter & Stay Updated
